
Ajanta Pharma Analyst Review 2027: Profit Up 49% as Brokers Split Between ₹3,908 and ₹4,250
Updated: 19 Nov 2026 • 9:26 am
Posted by:

Ajanta Pharma Stock Snapshot (18 Nov 2026 close)
- Current Market Price (CMP): ₹3,273.80
- 52-Week High / Low: ₹3,796.00 / ₹2,445.80
- Market Capitalisation: ₹40,885 crore
- P/E Ratio vs Industry P/E: 32.4 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: ₹1,794.16 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹388.14 crore
Quick Answer: The Ajanta Pharma analyst review 2027 shows a strong quarter and a split brokerage view. Q2 FY27 revenue rose about 32.5% to ₹1,794.16 crore and profit rose about 49.2% to ₹388.14 crore, with an adjusted EBITDA margin of 30.5% against guidance of 27% plus or minus 1%. PL Capital kept Buy and raised its target to ₹4,250 on 1 November 2026, while Systematix cut its rating to Hold with a ₹3,908 target. At ₹3,273.80, the Ajanta Pharma share price target 2027 range implies about 19% to 30% upside.
The Ajanta Pharma analyst review 2027 covers a Mumbai-based drug maker that earns most of its revenue from branded generics in India, Asia and Africa, with a growing US generics arm. Investors searching for an Ajanta Pharma share price target 2027 will find several named brokerage targets, and all of them sit above the current price.
Ajanta Pharma closed at ₹3,273.80 on 18 November 2026. That is about 14% below its 52-week high of ₹3,796 and about 34% above its low of ₹2,445.80. This Ajanta Pharma analyst review 2027 covers the brokerage views, the September quarter and what will drive the Ajanta Pharma stock outlook 2027.
Click Here – Get Free Investment Predictions
What Brokerages Say in the Ajanta Pharma Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| PL Capital (Prabhudas Lilladher) | Buy | ₹4,250 | 1 November 2026 |
| Systematix | Hold (downgraded) | ₹3,908 | After Q2 FY27, November 2026 |
| Motilal Oswal | Buy | ₹4,000 | July 2026 |
| ICICI Direct | Buy | ₹3,960 | August 2026 |
| ICICI Securities | Hold (downgraded) | ₹3,260 | July 2026 |
PL Capital called Q2 a strong beat and lifted its target to ₹4,250, noting that branded generics in India, Asia and Africa made up about 70% of FY26 revenue. Systematix moved to Hold after the rally, saying limited near-term upside remained to its ₹3,908 target, which is based on 35 times estimated FY28 earnings.
Motilal Oswal's ₹4,000 target and ICICI Direct's ₹3,960 target came after the June quarter. ICICI Securities downgraded to Hold at ₹3,260 in July on valuation, a level the stock now trades just above. Most brokerage targets in this Ajanta Pharma analyst review 2027 sit between ₹3,900 and ₹4,250.
Q2 FY27 Results in the Ajanta Pharma Analyst Review 2027
| Quarter | Total Income | EBITDA | Net Profit |
|---|---|---|---|
| Sep 2026 (Q2 FY27) | ₹1,831.55 crore | ₹584.95 crore | ₹388.14 crore |
| Jun 2026 (Q1 FY27) | ₹1,696.86 crore | ₹494.48 crore | ₹334.22 crore |
| Mar 2026 (Q4 FY26) | ₹1,483.07 crore | ₹394.84 crore | ₹266.70 crore |
| Dec 2025 (Q3 FY26) | ₹1,399.81 crore | ₹407.21 crore | ₹273.77 crore |
| Sep 2025 (Q2 FY26) | ₹1,413.07 crore | ₹387.17 crore | ₹260.19 crore |
Revenue from operations rose about 32.5% to ₹1,794.16 crore. Adjusted EBITDA margin reached about 30.5%, roughly 250 basis points above the guided band. Net profit rose about 49.2% to ₹388.14 crore, and EPS rose to ₹31.07.
India made up about 28% of revenue, Asia and Africa branded generics 38%, US generics 27% and Africa institutional 7%. US sales grew about 49% and Africa institutional about 259%, but management flagged both as partly one-off. For the Ajanta Pharma analyst review 2027, the branded businesses are the steady core.
How Ajanta Pharma Makes Money
Ajanta focuses on specialty branded medicines in therapy areas such as cardiology, ophthalmology, dermatology and pain, sold through its own sales teams.
- India branded: prescription brands sold through doctors. India volume grew about 18% in Q2 against a market growth of about 13%.
- Asia and Africa branded: branded generics in emerging markets, the largest segment.
- US generics: ANDA-based generic drugs sold in the US.
- Africa institutional: tender supplies, mainly anti-malarials.
Revenue rose from about ₹4,293 crore in FY24 to ₹4,743 crore in FY25 and ₹5,625 crore in FY26. Profit rose from ₹816 crore to ₹920 crore and then ₹1,056 crore. That steady compounding underpins the Ajanta Pharma analyst review 2027.
Growth Triggers in the Ajanta Pharma Analyst Review 2027
- Branded momentum: India volume growth of about 18% against the market's 13%.
- Asia recovery: shipments delayed in Q1 by Middle East disruption were restored in Q2.
- Margin beat: Q2 adjusted EBITDA margin of 30.5% against 27% plus or minus 1% guidance.
- Capacity: about ₹400 crore of FY27 capex, including expansion at existing sites.
- Clean balance sheet: debt to equity of about 0.03 supports the Ajanta Pharma share price target 2027 case.
Key Risks in the Ajanta Pharma Analyst Review 2027
- One-off growth: US and Africa institutional surges in Q2 are not expected to repeat.
- US competition: a limited-competition US product now faces new entrants.
- Geopolitics: Asia branded sales fell in Q1 because of Middle East disruption.
- Cost pressure: higher freight, raw material and field force costs.
- Valuation caution: two brokerages have moved to Hold, a signal worth weighing in the Ajanta Pharma analyst review 2027.
Compare Ajanta Pharma With Other Pharma Stocks on the Univest Screener
Ajanta Pharma Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (18 Nov 2026 close) | ₹3,273.80 |
| 52-Week High / Low | ₹3,796.00 / ₹2,445.80 |
| Market Capitalisation | ₹40,885 crore |
| P/E (TTM) vs Industry | 32.4 vs 40.1 |
| Price to Book | 8.42 |
| Book Value per Share | ₹388.78 |
| Return on Equity | 25.99% |
| Debt to Equity | 0.03 |
| Dividend Yield | 0.86% |
| FY26 Revenue / Net Profit | ₹5,625 crore / ₹1,056 crore |
A P/E of about 32 is below the pharma industry figure of about 40, while return on equity is about 26%. Price to book value of about 8.4 reflects those high returns. The Nifty Pharma index gives a sector benchmark for the Ajanta Pharma analyst review 2027.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 66.25% | 63.47% | Down 2.78 pts |
| Foreign Investors (FII) | 8.53% | 7.63% | Down 0.90 pts |
| Domestic Institutions (DII) | 17.90% | 21.94% | Up 4.04 pts |
| Public | 7.32% | 6.96% | Down 0.36 pts |
The Agrawal family promoter group holds 63.47%, down about 2.8 points over the year, with trusts of Rajesh and Yogesh Agrawal at 14.47% each. Domestic institutions added about 4 points, absorbing the promoter sale. That shift is worth tracking in the Ajanta Pharma analyst review 2027.
What to Watch After the Ajanta Pharma Analyst Review 2027
- Margins: whether EBITDA margin settles near the 27% guide or stays near 30%.
- US business: sales after new competition on its key product.
- Branded growth: India and Africa branded growth in H2 FY27.
- Promoter stake: any further reduction from 63.47%.
- Target revisions: more upgrades or downgrades would reset the Ajanta Pharma share price target 2027.
Final Word on the Ajanta Pharma Analyst Review 2027
The Ajanta Pharma analyst review 2027 shows a debt-free branded generics leader with profit up about 49%, margins above guidance and targets from ₹3,908 to ₹4,250 for the latest calls. Part of Q2 growth was one-off, and some brokerages now prefer to wait.
The Ajanta Pharma stock outlook 2027 depends on branded growth, US competition and margin discipline. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Ajanta Pharma analyst review 2027 show?
It shows strong growth and a split brokerage view. Q2 FY27 revenue rose about 32.5% to ₹1,794.16 crore and profit rose about 49.2% to ₹388.14 crore. Adjusted EBITDA margin was about 30.5%. PL Capital is at Buy while Systematix moved to Hold.
What is the Ajanta Pharma share price target 2027 from brokerages?
PL Capital has a Buy with ₹4,250 from 1 November 2026, and Systematix a Hold with ₹3,908. Motilal Oswal has ₹4,000 and ICICI Direct ₹3,960 from mid-2026. The stock closed at ₹3,273.80 on 18 November 2026.
Why did Ajanta Pharma profit jump in Q2 FY27?
Revenue grew about 32.5%, led by branded generics and strong US and Africa institutional sales. Adjusted EBITDA margin rose to about 30.5%. Management said parts of the US and institutional growth are not expected to repeat.
How does Ajanta Pharma make money?
It sells branded generics in India, Asia and Africa and generic drugs in the US. Branded generics were about 70% of FY26 revenue. FY26 revenue was about ₹5,625 crore and profit about ₹1,056 crore.
Is Ajanta Pharma stock expensive based on the Ajanta Pharma analyst review 2027?
The P/E of about 32 is below the industry figure of about 40. Return on equity is about 26% and debt to equity is about 0.03. Price to book is about 8.4.
What risks does the Ajanta Pharma analyst review 2027 highlight?
The main risks are one-off growth, US competition and cost pressure. US and Africa institutional surges are flagged as partly non-recurring. Two brokerages have Hold ratings on valuation.
What should investors track after the Ajanta Pharma analyst review 2027?
Track whether EBITDA margin stays near 30% or returns to the 27% guide. Watch US sales after new competition. Further promoter stake sales would also matter.
Recent Articles

Aeroflex Enterprises Analyst Review 2027: Profit Up 87% as Listed Subsidiary Drives the Group
19 November 2026

AGI Infra Analyst Review 2027: Profit Rises 39% as Jalandhar Developer Grows Every Quarter
19 November 2026

Aeroflex Industries Analyst Review 2027: Income Jumps 87% as Data Centre Cooling Takes Off
19 November 2026

Angel One Analyst Review 2027: Profit Jumps 58% on 45% Margins as MOFSL Holds ₹380 Target
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Aeroflex Enterprises Analyst Review 2027: Profit Up 87% as Listed Subsidiary Drives the Group
AGI Infra Analyst Review 2027: Profit Rises 39% as Jalandhar Developer Grows Every Quarter
Aeroflex Industries Analyst Review 2027: Income Jumps 87% as Data Centre Cooling Takes Off
Angel One Analyst Review 2027: Profit Jumps 58% on 45% Margins as MOFSL Holds ₹380 Target
Amagi Analyst Review 2027: Record Revenue and 30-Fold Profit Jump Test Early Broker Targets

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





